Open Access
Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial
Yunyun Xiong, Bruce C V Campbell, Marc Fisher, Lee H Schwamm, Mark Parsons, Hao Li, Yuesong Pan, Xia Meng, Xingquan Zhao, Yongjun Wang
DOI: 10.1136/svn-2023-002310 Published 27 February 2024
Yunyun Xiong
1
Neurology, Beijing Tiantan Hospital, Beijing, China
2
China National Clinical Research Center for Neurological Diseases, Beijing, China
Bruce C V Campbell
3
Department of Medicine and Neurology, The University of Melbourne, Melbourne, Victoria, Australia
Marc Fisher
4
Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Lee H Schwamm
5
Department of Neurology and Comprehensive Stroke Center, Massachusetts General Hospital, Boston, Massachusetts, USA
Mark Parsons
6
Department of Neurology, University of New South Wales South Western Sydney Clinical School, Liverpool, New South Wales, Australia
Hao Li
2
China National Clinical Research Center for Neurological Diseases, Beijing, China
Yuesong Pan
2
China National Clinical Research Center for Neurological Diseases, Beijing, China
Xia Meng
2
China National Clinical Research Center for Neurological Diseases, Beijing, China
Xingquan Zhao
1
Neurology, Beijing Tiantan Hospital, Beijing, China
Yongjun Wang
1
Neurology, Beijing Tiantan Hospital, Beijing, China
2
China National Clinical Research Center for Neurological Diseases, Beijing, China

Submit a Response to This Article
No eLetters have been published for this article.
Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial
Yunyun Xiong, Bruce C V Campbell, Marc Fisher, Lee H Schwamm, Mark Parsons, Hao Li, Yuesong Pan, Xia Meng, Xingquan Zhao, Yongjun Wang
Stroke and Vascular Neurology Feb 2024, 9 (1) 82-89; DOI: 10.1136/svn-2023-002310

Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial
Yunyun Xiong, Bruce C V Campbell, Marc Fisher, Lee H Schwamm, Mark Parsons, Hao Li, Yuesong Pan, Xia Meng, Xingquan Zhao, Yongjun Wang
Stroke and Vascular Neurology Feb 2024, 9 (1) 82-89; DOI: 10.1136/svn-2023-002310
Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial
Yunyun Xiong, Bruce C V Campbell, Marc Fisher, Lee H Schwamm, Mark Parsons, Hao Li, Yuesong Pan, Xia Meng, Xingquan Zhao, Yongjun Wang
Stroke and Vascular Neurology Feb 2024, 9 (1) 82-89; DOI: 10.1136/svn-2023-002310